A daily dose of adult-strength aspirin may modestly reduce cancer risk in populations with high rates of colorectal, prostate, and breast cancer if taken for at least five years.
Chemotherapy is frequently given to women with breast cancer after surgery to remove the main bulk of the tumor. A new Cochrane Systematic Review of existing data shows, however, that using chemotherapy to reduce the size of tumors before surgery does not compromise survival rates and enables women to retain better self-image and overall health because of the reduced impact of the surgery.
A cancer-suppressing gene has been successfully delivered into the tumors of stage four lung cancer patients via an intravenously administered lipid nanoparticle in a phase I clinical trial at the University of Texas M. D. Anderson Cancer Center. The gene, FUS1, also was found to be active in the metastatic nonsmall cell lung cancer tumors.
Researchers concluded that the synergistic combination of Reolysin and gemcitabine is a promising therapeutic regimen for study in clinical trials.
Services that help women understand the way that their inherited genetic make-up influences their risk of getting breast cancer ease distress and decrease their levels of cancer worry. There is, however, insufficient evidence to make recommendations about the best way of delivering these services.
The American Association for Cancer Research, together with the Food and Drug Administration and National Cancer Institute, today announces the formation of the AACR-FDA-NCI Cancer Biomarkers Collaborative to facilitate the use of validated biomarkers in clinical trials and ultimately in evidence-based oncology and cancer medicine.
Selenium may offer an intervention strategy for the treatment of prostate cancer according to results of a study from the laboratory of Allen Gao, PhD, which will be presented by Yan Hu, PhD, Departments of Medicine and Pharmacology and Therapeutics, Roswell Park Cancer Institute (RPCI) at the 2007 centennial meeting of the American Association for Cancer Research (AACR), April 14-18, in Los Angeles, CA.
Potential drug interactions from prescribed medications are common among cancer patients and may cause unnecessary harm, according to a study in the April 18 Journal of the National Cancer Institute.
An intriguing study, conducted in mice and supported by an ongoing examination of breast cancer patient records, suggests a link between the pulmonary inflammation seen in asthma and increased risk of lung metastasis.
Regular aspirin use was associated with lower cancer incidence and cancer mortality, but non-aspirin non-steroidal anti-inflammatory drug (NSAID) use was not, according to one of the largest studies ever conducted to look at the impact of these agents on overall cancer risk.